REFRACTORY
Clinical trials for REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY trials appear
Sign up with your email to follow new studies for REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug duo outsmart resistant lymphomas?
Disease control OngoingThis phase II trial is testing whether combining two drugs—pembrolizumab, an immunotherapy that helps the immune system attack cancer cells, and entinostat, a drug that may make cancer cells more visible to the immune system—can shrink lymphomas that have come back or stopped res…
Matched conditions: REFRACTORY
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gentler myeloma treatment shows promise for frail patients
Disease control OngoingThis study tests a combination of three drugs—isatuximab, pomalidomide, and dexamethasone—at lower doses than usual. It includes 6 patients with multiple myeloma that has returned or not responded to treatment, who are also vulnerable due to age or other health problems. The goal…
Matched conditions: REFRACTORY
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Armored immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …
Matched conditions: REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC